Join the Chronic Obstructive Pulmonary Disease group to help and get support from people like you.
Chronic Obstructive Pulmonary Disease News (Page 4)
Related terms: Chronic Obstructive Pulmonary Disease, Acute, Bronchitis, Chronic, Bronchitis with Airway Obstruction, Chronic Bronchitis, Chronic Obstructive Airway Disease, Chronic Obstructive Lung Disease, COPD, Acute, COPD, Maintenance, Emphysema, Chronic Obstructive Pulmonary Disease, Maintenance, COPD
Race-Neutral Metrics More Accurately Predict Risk in COPD
FRIDAY, May 31, 2024 – Race-neutral metrics more accurately predict the risk for death and exacerbations in chronic obstructive pulmonary disease (COPD), according to a study published online April...
Dupilumab Tied to Fewer Exacerbations in COPD With Type 2 Inflammation
TUESDAY, May 21, 2024 – Dupilumab is associated with fewer exacerbations for patients with chronic obstructive pulmonary disease (COPD) with type 2 inflammation, according to a study published...
Researchers Compare Race-Based, Race-Neutral Lung Function Equations
TUESDAY, May 21, 2024 – The use of race-based and race-neutral equations for lung-function testing generate similarly accurate predictions of respiratory outcomes, but differ in terms of disease...
Pulmonologist Intervention Beneficial for Undiagnosed Asthma, COPD
TUESDAY, May 21, 2024 – For adults with undiagnosed asthma and chronic obstructive pulmonary disease (COPD), receipt of pulmonologist-directed treatment is associated with less subsequent health...
Bisoprolol Does Not Reduce Exacerbations in At-Risk COPD Patients
MONDAY, May 20, 2024 – For patients with chronic obstructive pulmonary disease (COPD), bisoprolol does not reduce the number of self-reported exacerbations treated with oral corticosteroids,...
FDA Approves Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) for the Maintenance Treatment of COPD
24 July 2020 – AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the maintenance treatment of patients with chronic obstructive p...
FDA Approves Duaklir Pressair (aclidinium bromide and formoterol fumarate) for Maintenance Treatment of Chronic Obstructive Pulmonary Disease
Oxford, UK – 1 April 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US Food and Dr...
FDA Approves ProAir Digihaler (albuterol sulfate) as the First and Only Digital Inhaler with Built-In Sensors
JERUSALEM--(BUSINESS WIRE)--Dec 21, 2018--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ProAir ® Digihaler™ (a...
FDA Approves Yupelri (revefenacin) for Chronic Obstructive Pulmonary Disease (COPD)
DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 9, 2018 /PRNewswire/ – Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today...
Once-Daily Trelegy Ellipta Gains Expanded Indication in the US for the Treatment of Patients with COPD
24 April 2018 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved an expanded indication for Trelegy...
FDA Medwatch Alert: Long-Acting Beta agonists (LABAs) and Inhaled Corticosteroids (ICS): Drug Safety Communication - Boxed Warning About Asthma-Related Death Removed
ISSUE: FDA's most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large...
Sunovion Receives FDA Approval for Lonhala Magnair (glycopyrrolate) Inhalation Solution to Treat COPD
MARLBOROUGH, Mass.--(BUSINESS WIRE) December 5, 2017 --Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application...
FDA Approves Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for the Treatment of COPD
London UK – 18 September 2017 – GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single i...
Bevespi Aerosphere Approved by the FDA for Patients with COPD
25 April 2016 – AstraZeneca today announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the...
FDA Approves Seebri Neohaler (glycopyrrolate) for COPD
EAST HANOVER, N.J., Oct. 29, 2015 Novartis announced today that the US Food and Drug Administration (FDA) has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 mcg as a stand-alone...
Further information
Related drug support groups
prednisone, albuterol, Symbicort, Dupixent, Trelegy Ellipta, montelukast, dupilumab, Anoro Ellipta